How to adapt medicine dosages to children? And reduce risks of dose errors?
Children and elderly people need drug doses that are tailored to their bodyweight or to their condition.
There are currently limited suitable solutions for selecting a variable dose and delivering it easily and accurately. Indeed, a lot of patients suffer from adverse events due to dosage errors.
1 child every 8 minutes experienced out-of-hospital medication errors.
More than 66% of preventable adverse drug events were due to parental errors in administering drugs.
1 in 4 caregivers gave a dose that deviated by more than 40%.
96.4% are ingestion route of exposure.
WHY POWDOSE
The oral drug primary packaging with dosing feature for personalized medicine
Child resistant design focused on usability, ease of use and human errors minimization. First user study conducted with good results.
Ready-to-use and prefilled with the oral medicine
Compliant with ISO 13485 and IP filed
Made of environmentally friendly sustainable polymers
Partnership
The POWDOSE solution is provided to B2B pharmaceutical customers who want to combine an innovative primary packaging dosing device with their medicine.
The drug remains in dry solid form until the administration, which enhances the in-use stability and the access to the medicine.
If you have a candidate drug that would profit from the POWDOSE solution, reach out to us! We would be happy to launch an innovation co-development program with your pharma company for tailoring the dose ranges of POWDOSE to your medicine and therapy.
The POWDOSE reduces the adverse events of dosage errors while improving user experience.
The POWDOSE adds value to the drug product and propose a differentiation against the competition.
The POWDOSE is a platform applicable to any powder or granulate-based medicine where the dose needs to be tailored to the patient’s bodyweight and condition.
Leadership
Management
Strong Independent US/EU Board
Thierry Jomini
CEO - Founder (based in CH - Lausanne)
15 years’ experience in leading drug delivery devices and combination products development for various application such as diabetes, Parkinson disease or hormone therapies.
Stephen M. Perry
CEO - Founder (based in RTP/USA)
He is the CEO and Founder of Kymanox where he leads a team of 300 professionals worldwide and has been formally recognized as a top CEO in the Research Triangle Park (RTP) region. He has successfully attracted growth capital from investors and has further grown the unique Kymanox platform with the acquisition of four companies. He has also helped several CEOs raise Series A venture capital.
Greg Cash
Chairman - Founder (Minneapolis)
Transformational and innovative life sciences CEO with a proven track record of growing and turning around businesses with significant value creation. Domain expertise in medical devices, mobile and digital health and pet health. Has been Chief Executive of several medical device companies, both public and privately held, as well as run units of larger entities.
Dr. Dirk Kreder
Entrepreneur, Investor and Senior Advisor (Munich)
25 years of experience in small and mid-size biotech and global pharma companies in the US and Europe with focus on Medical Device and drug development and registration. Dirk is a recognized leader in North America, Europe, and Asia to support customers in Pharma and Biotech, especially Biosimilar developers, in their medical device needs.
Paul Dunne
Entrepreneur and Business Development Manager (Dublin/Austria)
An experienced Commercial manager in the pharmaceutical industry with over 15 years working in the CDMO and R&D field facilitating interactions with Large Pharma, Biotech and Generic manufactures. Paul was co-founder of Advande Labs. A fully GMP FDA accredited analytical laboratory servicing the international pharma, Biotech, Nutraceutical and Veterinary industry.
Latest Updates
Follow POWDOSE project
The PCT application for the patent of POWDOSE has been filed!
We’ll be exhibiting at CPHI in Barcelone on Oct 24-26. Don’t hesitate to visit us at the booth 3QS02.
Contact / Investors
Don’t hesitate to contact us
Chemin de Pramey 18
1530 Payerne
Switzerland
info@abbatialabs.com
AbbatiaLabs is a startup specialized in innovation at the edge of medical technologies and pharmaceutical development. We want to set a new standard for children and elderly healthcare.
We are offering the opportunity to invest responsibly and have a huge impact in children healthcare. We are keen to sustainable funding for growing our company independently.
Contact us